brand logo

Am Fam Physician. 2023;107(3):309-310

Author disclosure: No relevant financial relationships.

Viloxazine (Qelbree) is a selective norepinephrine reuptake inhibitor labeled for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and children older than six years.1

DrugDosageDose formCost of full course*
Viloxazine (Qelbree)Children 6 to 11 years: 100 to 400 mg per day, starting at 100 mg daily and titrating by 100 mg weekly to effective dose100-mg, 150-mg, 200-mg capsules$330
Adults: 200 to 600 mg per day, starting at 200 mg daily and titrating by 200 mg weekly to effective doseMay be swallowed whole or opened and sprinkled on food
Already a member/subscriber?  Log In


From $165
  • Immediate, unlimited access to all AFP content
  • More than 130 CME credits/year
  • AAFP app access
  • Print delivery available

Issue Access

  • Immediate, unlimited access to this issue's content
  • CME credits
  • AAFP app access
  • Print delivery available
Purchase Access:  Learn More

STEPS new drug reviews cover Safety, Tolerability, Effectiveness, Price, and Simplicity. Each independent review is provided by authors who have no financial association with the drug manufacturer.

This series is coordinated by Allen F. Shaughnessy, PharmD, assistant medical editor.

A collection of STEPS published in AFP is available at

Continue Reading

More in AFP

More in PubMed

Copyright © 2023 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.